News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis Awarded $1m Australian Government Funding to Progress Duchenne Muscular Dystrophy Drug into the Clinic
Pharmaceutical research company Pharmaxis Ltd today announced it has been awarded $1 million funding from the Biomedical Translation Bridge (BTB) program to significantly advance work on the company’s drug discovery for the treatment of the devastating genetic disorder Duchenne Muscular Dystrophy (DMD).
Pharmaxis was selected following a highly competitive review conducted by an independent expert evaluation committee as part of the BTB program, which is administered by MTPConnect. The Australian government matched funding will allow the company to take another one of its pipeline of amine oxidase inhibitors (PXS-4699) through to the commencement of human clinical trials. A planned comprehensive program of pre-clinical studies will build on the pioneering work already conducted on Pharmaxis compounds by independent international researchers focused on Duchenne Muscular Dystrophy. PXS-4699 is a dual amine oxidase inhibitor which is expected to protect muscle and reduce inflammation as well as organ fibrosis in DMD. It is hoped this could result in better daily functioning for patients, improved quality of life and longer life expectancy.
Read full media release - pdfFDA Gives Pharmaxis Green Light to Start Myelofibrosis Phase 2 Study
Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) announced that the Food and Drug Administration (FDA) has completed a safety review of the company’s Investigational New Drug (IND) application for the pan-LOX inhibitor PXS-5505 and given Pharmaxis permission to proceed with a phase 1/2 clinical trial for the treatment of myelofibrosis in adults.
Read full media release - pdfResignation of Non Executive Director Edward Rayner
Pharmaceutical research company Pharmaxis (ASX: PXS) today announced that its non-executive director Mr Edward Rayner has resigned from the Board effective 14 August 2020.
Mr Rayner joined the Pharmaxis Board in conjunction with a share placement to UK based Arix Bioscience plc in September 2018. At the time he was the investment director leading the Arix investment. Mr Rayner has recently commenced a new executive position with a UK life science technology company, having left Arix earlier this year.
Pharmaxis Chairman Malcolm McComas said, “We will miss Ed’s contribution as an experienced global specialist biotech investor, but we understand his need to focus on his new position and wish him well.”